Innovent Buys Into Ascentage, Opening New China Biopharma Chapter
Combining Small, Large Molecule Expertise
The unprecedented deal between two public Chinese biotechs, Innovent Biologics and Ascentage Pharma, potentially provides an opening for more such mega-million dollar deals to come.
You may also be interested in...
Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.